Abstract

Severe acute respiratory syndrome coronavirus 2 virus (SARS-CoV-2) was detected as a causative agent of acute respiratory diseases in Wuhan in China in December 2019, and it quickly spread all over the world. The severity of the disease changes from person to person. Some patients have mild symptoms, while it causes severe respiratory failure and death in other patients. The reason for this difference is innate and adaptive immune response of the individual. Hyper-inflammation and cytokine storm syndrome were observed in patients with severe Coronavirus 2019 (Covid-19) infection. T cell receptor was replaced by chimeric antigen receptor in genetically modified Chimeric Antigen Receptor T cells for B cell lymphoma and leukemia treatment. This chimeric antigen receptor is specific to tumor antigens. Thus, T cells can recognize and kill tumor cells. This approach can be used for covid-19 treatment; however, there has been no completed study, yet.